Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 2, 1999, Pages 85-90

  Matsuzaki, Jo ^a   Yamamoto, Chika ^a   Miyama, Tetsuo ^a   Takanaga, Hitomi ^a   Matsuo, Hirotami ^a   Ishizuka, Hitoshi ^b   Kawahara, Yukinori ^b   Kuwano, Michihiko ^c   Naito, Mikihiko ^d   Tsuruo, Takashi ^d   Sawada, Yasufumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

blocker; Blood brain barrier; Bunitrolol; P glycoprotein

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNITROLOL; CYCLOSPORIN A; GLYCOPROTEIN P; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CELL CULTURE; CELL LEVEL; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG TRANSPORT; GENE DISRUPTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CYCLOSPORINE; ENZYME INHIBITORS; HUMANS; KB CELLS; KINETICS; L CELLS (CELL LINE); MICE; P-GLYCOPROTEIN; PROPANOLAMINES; TRITIUM; VERAPAMIL; VINBLASTINE;

EID: 0032998117     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199903)20:2<85::AID-BDD159>3.0.CO;2-3     Document Type: Article

References (27)

1. T.A. Betts and C. Alford, β-Blocking drugs and sleep: a controlled trial. Drugs, 25 (Suppl 2), 268-272 (1983).
2. T.A. Betts and C.A. Alford, β-Blocking drugs and sleep: a controlled trial. Prim. Cardiol., 1 (Suppl), 201-205 (1983).
3. T.A. Betts and C.A. Alford, β-Blockers and sleep: a controlled trial. Eur. J. Clin. Pharmacol., 28, 65-68 (1985).
4. W.P. Koella, β-Blockers and CNS side-effects: CNS-related (side-)effects of β-blockers with special reference to mechanisms of action. Eur. J. Clin. Pharmacol., 28, 55-63 (1985).
5. J.B. Kostis and R.C. Rosen, Beta-blocker effects on central nervous system: a controlled comparative study. J. Am. Coll. Cardiol., 7, 25A (1986).
6. J.B. Kostis and R.C. Rosen, Central nervous system effects of β-adrenergic-blocking drugs: the role of ancillary properties. Circulation, 75, 204-212 (1987).
7. D.N. Middlemiss, L.B. Blakeborough and S.R. Leather, Direct evidence for an interaction of β-adrenergic blockers with the 5-HT receptor. Nature, 267, 289-290 (1977).
8. Y. Yamada, K. Ito, K. Nakamura, Y. Sawada and T. Iga, Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure-pharmacokinetic/pharmacodynamic relationship. Biol. Pharm. Bull., 16, 1251-1259 (1993).
9. J. Hamada, Y. Sawada, K. Nakamura, Y. Yamada and T. Iga, Prediction and evaluation of penetration of drugs into cerebrospinal fluid in human. Jpn. J. Hosp. Pharm., 18, 349-360 (1992).
10. T.H. Lin, Y. Sawada, T. Iga and M. Hanano, Effects of albumin and alpha 1-acid glycoprotein on the transport of imipramine and desipramine through the blood-brain barrier in rats. Chem. Pharm. Bull., 35, 294-301 (1987).
11. P. Borst A.H. Schinkel, J.J. Smit, E. Wagenaar, L. Van Deemter, A.J. Smith, E.W. Eijdems, F. Baas, G.J. Zaman, Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther., 60, 289-299 (1993).
12. A.H. Schinkel, J.J.M. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, C.A.A.M. Mol, M.A. van der Valk, E.C. Robanus-Maandag, H.P.J. te Riele, A.J.M. Berns and P. Borst, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491-502 (1994).
13. A.H. Schinkel, E. Wagenaar, C.A.A.M. Mol and L. van Deemter, P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 97, 2517-2524 (1996).
14. T. Rikihisa, S. Toyama, M. Mori, T. Suzuki, Influence of the route of administration on the metabolism of a beta-adrenergic blocker, o-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile (bunitrolol). Yakugaku Zasshi - J. Pharm. Soc. Japan, 98, 1258-1266 (1978).
15. T. Suzuki and T. Rikihisa, Studies on absorption, distribution and excretion of a β-adrenergic blocking agent, in rat and mice. Arzneim.-Forsch. Drug Res., 29, 1707-1715 (1979).
16. K. Kohno, J. Kikuchi, S. Sato, H. Takano, Y. Saburi, K. Asho and M. Kuwano, Vincristine-resistant human cancer KB cell line and increased expression of multidrug-resistant gene. Jpn. J. Cancer Res. (Gann), 79, 1238-1246 (1988).
17. H. Kusaba, K. Kohno, K. Asakuno, M. Kuwano, K. Okumura, E.D. Green, D. Schlessinger and M. Wada, Functional expression of yeast artificial chromosome-human multidrug resistance genes in mouse cells. Gen. Res., 5, 245-258 (1995).
18. K. Koike, T. Abe, T. Hisano, T. Kubo, M. Wada, K. Kohno and M. Kuwano, Overexpression of multidrug resistance protein gene in human cancer cell line selected for drug resistance to epipodophyllotoxins. Jpn. J. Cancer. Res., 87, 765-772 (1996).
19. T. Tatsuta, M. Naito, T. Oh-hara, I. Sugawara and T. Tsuruo, Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem., 267, 20383-20391 (1992).
20. T. Tatsuta, M. Naito, T. Oh-hara, I. Sugawara and T. Tsuruo, Enhanced expression by the brain matrix of P-glycoprotein in brain capillary endothelial cells. Cell Growth Different., 5, 1145-1152 (1994).
21. Y. Tanigawara, N. Okamura, M. Hirai, M. Yasuhara, K. Ueda, N. Kioka, T. Kommano and R. Hori, Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Biol. Chem., 263, 840-845 (1992).
22. K. Ueda, N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, T. Komano and R. Hori, Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem., 267, 24248-24252 (1992).
23. O.H. Lowry, N.J. Rosebrough, A.L. Farr and R.J. Randall, Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275 (1951).
24. J. Karlsson, S.M. Kuo, J. Ziemniak and P.A. Artursson, Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol., 110, 1009-1016 (1993).
25. S.M. Kuo, B.R. Whitby, P.A. Artursson and J.A. Ziemniak, The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm. Res., 11, 648-653 (1994).
26. T. Terao, E. Hisanaga, Y. Sai, I. Tamai and A. Tsuji, Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol., 48, 1083-1089 (1996).
27. D.F. Tang-Wai, S. Kajiji, F. DiCapua, D. de Graaf, I.B. Roninson and P. Gros, Human (MDR1) and mouse (mdr1 and mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry, 34, 32-39 (1995).